title: [Novel therapy for atherosclerosis and inflammatory vascular disease].
abstract: How to manage residual atherosclerosis risk after the statin therapy is a major concern in cardiovascular medicine. In addition to life-style modifications, new drugs against atherosclerotic and inflammatory vascular diseases are expected. In current clinical trials, phospholipase A2 inhibitors(darapladib, varespladib), RVX-208, D-4F, CETP inhibitors (anacetrapib, dalcetrapib), succinobucol are investigated. Some has been failed, but others are still promising. On molecular target basis of PAF-AH, CETP, PON, ABC transporters of A1 and G1, SR-BI, HO-1, potential benefits and side effects are discussed.
authors.affiliation: Department of Laboratory Sciences, School of Health Sciences, Kanazawa University.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Inazu
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000577:Amides; D016632:Apolipoprotein A-I / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology; D001547:Benzaldehydes / Q000627:therapeutic use; D001798:Blood Proteins / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D015195:Drug Design; D004952:Esters; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007651:Keto Acids; D058990:Molecular Targeted Therapy; D023303:Oxazolidinones / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D011341:Probucol / Q000031:analogs & derivatives / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D052999:Quinazolinones; D013438:Sulfhydryl Compounds / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
chemical_list: D000085:Acetates; D000577:Amides; D016632:Apolipoprotein A-I; D001547:Benzaldehydes; D001798:Blood Proteins; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D007211:Indoles; D007651:Keto Acids; D023303:Oxazolidinones; D010091:Oximes; D011341:Probucol; D011799:Quinazolines; D052999:Quinazolinones; D013438:Sulfhydryl Compounds; C465468:D-4F peptide; C400481:PLIalpha; C117948:varespladib; C411602:dalcetrapib; C000628794:apabetalone; C471047:succinobucol; C530884:anacetrapib; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides